2014
Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study. Journal Of Clinical Oncology 2014, 32: 927-934. PMID: 24516021, PMCID: PMC3948095, DOI: 10.1200/jco.2013.51.1261.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerCardiac eventsOlder patientsBreast cancerTrastuzumab completionAdjuvant trastuzumabTreatment completionOlder womenHuman epidermal growth factor receptorAdjuvant trastuzumab useAge 76 yearsDays of therapyMost older patientsSignificant cardiac eventsMultivariable logistic regressionEpidermal growth factor receptorGrowth factor receptorMore comorbiditiesTrastuzumab useComorbidity scorePatient ageHospital admissionOptimal treatmentLower oddsMedicare data
2013
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Annals Of Oncology 2013, 24: 1434-1443. PMID: 23425944, DOI: 10.1093/annonc/mdt025.Peer-Reviewed Original ResearchConceptsMale breast cancerMale breast cancer patientsBreast cancer patientsRisk factorsBreast cancerSurvivorship issuesCancer patientsEstrogen/androgen ratioMale breast carcinomaEnglish-language literatureEndocrine therapyAndrogen ratioOptimal treatmentBRCA2 mutationsBreast carcinomaPsychosocial sequelaeSystematic reviewPsychosocial impactDiagnostic approachLanguage literaturePatientsCancerAppropriate evaluationDisease biologyMen